Last reviewed · How we verify

Voranigo — Competitive Intelligence Brief

Voranigo (VORASIDENIB) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Isocitrate Dehydrogenase 1 Inhibitor [EPC]. Area: Oncology.

marketed Isocitrate Dehydrogenase 1 Inhibitor [EPC] Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Voranigo (VORASIDENIB) — Servier. Voranigo works by blocking the activity of an enzyme called isocitrate dehydrogenase 1.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Voranigo TARGET VORASIDENIB Servier marketed Isocitrate Dehydrogenase 1 Inhibitor [EPC] 2025-01-01
Tibsovo IVOSIDENIB Servier marketed Isocitrate Dehydrogenase 1 Inhibitor [EPC] mutant IDH1 2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Isocitrate Dehydrogenase 1 Inhibitor [EPC] class)

  1. Servier · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Voranigo — Competitive Intelligence Brief. https://druglandscape.com/ci/vorasidenib. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: